FDA 发布草案指南,拟简化部分个体化基因治疗审批路径
STAT+: FDA offers new details on quicker approval pathway for personalized gene therapies
FDA 于周二发布草案指南,拟简化部分个体化基因治疗的审批流程。罕见病倡导者此前批评 FDA 对这类疗法的处理方式,PKD Foundation 的 Paul Scribner 称该草案相当于明确表态这类疗法重要。原文为 STAT+ 付费内容,其余细节未公开。
WASHINGTON – The Food and Drug Administration published draft guidance on Tuesday that would streamline approvals of some individualized gene therapies, a win for rare disease advocates who have criticized the agency’s approach to these treatments.
“It’s sort of putting a flag in the ground and saying, ‘This is important,’” Paul Scribner, vice president of community programs and education at the PKD Foundation, said of the draft guidance at a rare disease event on Tuesday.
Breakthroughs in gene therapies, or treatments that treat or cure diseases by altering faulty genes inside a person’s cells, have energized researchers and companies who believe many patients with rare mutations could benefit from these personalized medicines.
STAT+ Exclusive Story
Already have an account? Log in

This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
来源:STAT Pharma 医药频道 · statnews.com